U
Medicus Pharma Ltd. MDCX.V
TSX
Recommendation
Prev Close
$5.69
Volume
--
Avg Vol (90D)
345
Market Cap
$46.91M
Dividend & Yield
--
52-Week Range
$2.55 - $7.60
P/E (TTM)
--
EPS (TTM)
--
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Medicus Pharma (NASDAQ:MDCX) Now Covered by Analysts at D. Boral Capital
4/17/2025 - Zolmax
Medicus Pharma (MDCX) Initiated with Buy Rating and $14 Price Target MDCX Stock News
4/14/2025 - GuruFocus
Medicus Pharma initiated with a Buy at D. Boral Capital
4/14/2025 - TipRanks Financial Blog
Medicus Pharma initiated with bullish view at D. Boral Capital, here's why
4/14/2025 - The Fly
Medicus Pharma (NASDAQ:MDCX) Announces Earnings Results, Beats Estimates By $0.14 EPS
3/30/2025 - Ticker Report
Medicus Pharma Ltd. Announces Closing of $4.2 Million Regulation A Offering
3/10/2025 - Newsfile Corp. - News Releases
Medicus Pharma CEO discusses latest skin cancer trial results - ICYMI
3/8/2025 - Proactive Investors - UK
Small cap wrap: G Mining Ventures, Wedgemount Resources, Medicus Pharma...
3/7/2025 - Proactive Investors - UK
Medicus Pharma unveils pricing of financing to advance skin cancer treatment
3/7/2025 - Proactive Investors - UK
Medicus Pharma Ltd. Announces Pricing of $4.2 Million Regulation A Offering
3/7/2025 - Newsfile Corp. - News Releases
Clinical Study SKNJCT-003 shows positive trends as company advances skin cancer research in UAE
3/6/2025 - Proactive Investors - UK
Small cap wrap: Petro-Victory Energy, NexTech3D.ai, Medicus Pharma, Nano One Technology...
3/6/2025 - Proactive Investors - UK
Market movers: Tesla, Marvell, Petro-Victory, Medicus Pharma...
3/6/2025 - Proactive Investors - UK
Medicus Pharma reports over 60% complete clearance in Phase 2 BCC trial interim results
3/6/2025 - Proactive Investors - UK
Medicus Pharma Ltd Announces Positively Trending Interim Analysis for SKNJCT-003 Phase 2 ...
3/6/2025 - GuruFocus
Medicus Pharma announces positively trending interim analysis for SKNJCT-003
3/6/2025 - TipRanks Financial Blog
Medicus Pharma announces positively trending interim analysis for SKNJCT-003
3/6/2025 - The Fly
Medicus Pharma Ltd Announces Positively Trending Interim Analysis for SKNJCT-003 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)
3/6/2025 - Newsfile Corp. - News Releases
Medicus Pharma Ltd Announces Positively Trending Interim Analysis for SKNJCT-003 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)
3/6/2025 - Globe Newswire
Small cap headlines: Alvopetro Energy, Delivra Health, Medicus Pharma, Aftermath Silver...
2/27/2025 - Proactive Investors - UK
Market movers: Ideal Power, Tiziana Life Sciences, Medicus Pharma...
2/27/2025 - Proactive Investors - UK
Medicus Pharma expands basal cell carcinoma trial in the Middle East
2/27/2025 - Proactive Investors - UK
Medicus Pharma submits Phase 2 skin cancer trial design to UAE Department of Health
2/27/2025 - Proactive Investors - UK
Medicus Pharma Submits Phase 2 Clinical Design for Skin Cancer Treatment in UAE
2/27/2025 - TipRanks Financial Blog
Medicus Pharma submits Phase 2 carcinoma clinical design in UAE
2/27/2025 - The Fly
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
--
EBIT (TTM)
--
Net Income (TTM)
--
Balance Sheet
Total Assets (Q)
--
Total Debt (Q)
--
Total Liabilities (Q)
--
Book Value Per Share (Q)
--
Cash Flow
Cash from Operations (TTM)
--
Cash from Investing (TTM)
--
Cash from Financing (TTM)
--
Net Change in Cash (TTM)
--
Filings
Filing Date
Period Date
Next Filing
(est)
Price History
Loading...
Beta
--
7-Day Total Return
0.00%
30-Day Total Return
0.00%
60-Day Total Return
42.25%
90-Day Total Return
44.05%
Year to Date Total Return
44.05%
1-Year Total Return
25.33%
2-Year Total Return
--
3-Year Total Return
--
5-Year Total Return
--
52-week Low
Nov 21, 2024 - $2.55
52-week High
Oct 07, 2024 - $7.60
Valuation
Market Cap
$46.91M - Nano Cap
Enterprise Value
--
Price/Sales (TTM)
--
Price/Book (Q)
--
Dividends and Shares
Shares Outstanding
--
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
medicuspharma.com
Phone Number
610-636-0184
Address
One First Canadian Place
Suite 3400 - 100 King Street West
Toronto, ON M5X 1A4
Country
Canada
Year Founded
2015
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Medicus Pharma Ltd., a biotech/life sciences company, focused on accelerating the clinical development programs of novel and disruptive therapeutic assets. The company is developing SkinJect... more